Advertisements



We are Sorry, This Page doesn't Exist


Here Comes Obesity Drug Competition: Amgen Shares Soar On "Very Encouraging" Clinical Trial Update

Here Comes Obesity Drug Competition: Amgen Shares Soar On "Very Encouraging" Clinical Trial Update Amgen's shares soared in premarket trading in New York following the drug maker's announcement of "very encouraging" clinical trial results f.....»»

Category: smallbizSource: nytMay 3rd, 2024

AstraZeneca"s Imfinzi/Chemo Combo Doubles Overall Survival In Biliary Tract Cancer Patients At 3 Years, Data Shows

AstraZeneca's updated data from TOPAZ-1 Phase 3 trial of Imfinzi (durvalumab) in advanced biliary tract cancer patients. Unveiling long-term survival benefits and significant overall survival improvement. read more.....»»

Category: blogSource: benzingaApr 16th, 2024

Small-Cap Cancer Drug Developer Agenus" Highlights Encouraging Data From Colorectal Cancer, But Funding Concerns Loom

The latest Phase 1 trial results of Agenus' botensilimab and balstilimab (BOT/BAL) combination therapy for metastatic CRC showcase promising clinical activity. Latest Ratings for A.....»»

Category: blogSource: benzingaApr 12th, 2024

AstraZeneca to present update on ph3 trial of LYNPARZA in early breast cancer

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMay 19th, 2021

Myovant"s stock falls after FDA puts partial clinical hold on trial for contraceptive candidate

Shares of Myovant Sciences Ltd. were down 5.7% in premarket trading on Wednesday after the company told investors that the Food and Drug Administration had placed a partial clinical hold on a study assessing an experimental birth c.....»»

Category: topSource: marketwatchMay 19th, 2021

BioLine RX rockets on heavy volume after "strikingly positive" trial data on cancer treatment

Shares of BioLine RX Ltd. rocketed 60% toward a 2-year high in very active trading Tuesday, enough to pace all of the premarket gainers, after the biopharmaceutical company announced positive results from a Phase 3 trial of its treatment for multi.....»»

Category: topSource: marketwatchMay 4th, 2021

Reviva"s stock jumps after experimental schizophrenia drug meets endpoint in Phase 2 clinical trial

Shares of Reviva Pharmaceuticals Holdings Inc. soared 76.6% in trading on Monday after the company said its experimental treatment .....»»

Category: topSource: marketwatchApr 26th, 2021

Novartis" Canakinumab Fails To Improve Survival In Late-Stage Lung Cancer Trial

Novartis AG (NYSE: NVS) reported data from the read more.....»»

Category: blogSource: benzingaMar 9th, 2021

GSK to refocus study of experimental COVID-19 antibody treatment on patients 70 and older

Shares of GlaxoSmithKline were down 0.2% in trading on Thursday after the drug maker said its experimental monoclonal antibody treatment did not meet the primary endpoint in a mid-stage trial evaluating its use in hospitalized COVID-19 patients of all a.....»»

Category: topSource: marketwatchFeb 25th, 2021

AstraZeneca exec tells Congress it could have 50 million doses of its COVID-19 vaccine ready in April

Shares of AstraZeneca were up 0.1% in after-hours trading on Tuesday after a company executive testified before Congress that the drug maker expec.....»»

Category: topSource: marketwatchFeb 23rd, 2021

Heat Biologics stock more than doubles after "positive" trial data of its lung cancer treatment

Shares of Heat Biologics Inc. more than doubled in very active trading Tuesday, after the biopharmaceutical company focused on modulating the immune system reported "positive" in.....»»

Category: topSource: marketwatchFeb 9th, 2021

Immunovant plunges nearly 50% after pausing a trial for its eye drug after unexpected cholesterol finding

Shares of Immunovant lost nearly half their value on Tuesday after the company announced a voluntary pause of trials of its IMVT-1401 eye drug. A researcher works on a vaccin against the new coronavirus COVID-19 at .....»»

Category: dealsSource: nytFeb 2nd, 2021

Myovant shares soar 27% on news of Pfizer prostate cancer drug collaboration worth up to $4.2 billion

Shares of Myovant.....»»

Category: topSource: marketwatchDec 28th, 2020

UPDATE: Myovant shares soar 20% premarket on news of Pfizer cancer drug deal worth up to $4.2 billion

Shares of Myovant Sciences soared 20% in premarket trade Monday, after its parent Sumitovant Biopharma said Myovant wi.....»»

Category: topSource: marketwatchDec 28th, 2020

Myovant shares soar 16% premarket on news of Pfizer cancer drug deal worth up to $4.2 billion

Shares of Myovant Sciences soared 16% in premarket trade Monday, after its parent Sumitovant Biopharma said .....»»

Category: topSource: marketwatchDec 28th, 2020

Akebia"s shares jump on late-stage clinical trial results for kidney disease drug

Shares of Akebia Therapeutics Inc. gained 30% in premarket trading on.....»»

Category: topSource: marketwatchMay 5th, 2020

Axsome Shares Jump 25% on Alzheimer’s Study Results

Clinical trial of AX-05 showed drug reduces patient agitationRelated Stocks: AXSM, LLY, RHHBY, ACIU, MOR, ESALY, BIIB,.....»»

Category: blogSource: gurufocusApr 28th, 2020

Saint Luke"s cardiologist leads trial to see if diabetes drug can prevent serious Covid-19 complications

Saint Luke's Mid America Heart Institute and drug company AstraZeneca PLC are conducting a clinical trial to see if a drug now used to treat diabetes could help prevent deadly complications in Covid-19 patients. The DARE-19 trial involves dapagliflozin,.....»»

Category: topSource: bizjournalsApr 25th, 2020

Why BioSig Technology"s Stock Is Trading Higher Friday

BioSig Technology (NASDAQ: BSGM) shares are trading higher on Friday after the company's subsidiary VirtalClear submitted an investigational new drug application to the FDA for a Phase 2 clinical trial of Merimepodib. read more.....»»

Category: blogSource: benzingaApr 24th, 2020

Gilead stock tumbles after Stat report on weak data in remdesivir trial in China

Shares of Gilead Sciences Inc. were down 5.3% in trading on Thursday after a Stat News report said a draft of the clinical trial results for remdesivir, an experimental drug being tested as a treatment for COVID-19, showed that the drug did not spe.....»»

Category: topSource: marketwatchApr 23rd, 2020